Viriom's Elsulfavirine (Elpida™)-based regimens for treatment of HIV-1 infection will be available to all patients and physicians in both regionally and federally funded programs in Russia.
SAN DIEGO, Sept. 5, 2018 -- Viriom, Inc., a San Diego-based biotech, announces that on Sept 4th, 2018, the commission of the Russian Ministry of Health included Elpida™, Viriom's once-daily 20 mg oral formulation of its innovative drug elsulfavirine, in Russia's List of Vital and Essential Drugs (VED).
Inclusion of Elpida™, Viriom's best in class non-nucleoside reverse transcriptase inhibitor (NNRTI), provides full access to the drug for all patients and physicians for HIV treatment and prophylaxis, and is chiefly funded under the Russian Government's State Strategy and Implementation Plan on HIV until 2020 and beyond.
The decision to list Elpida™ in VED was based on evaluation of Elpida's medical and pharmacoeconomic merit, and paves the way for quick adoption of Elpida™ as the preferred NNRTI standard of care by the regulatory and physician community, with strong support from patient organizations.
NNRTIs block HIV by inhibiting a key enzyme in virus replication. During preclinical and clinical development, elsulfavirine demonstrated a higher genetic barrier to development of resistance-conferring viral mutations, high efficacy, superior safety and tolerability over other antiretroviral medicines; and clinical pharmacology advantageous for development of less frequent drug administration.
Viriom, Inc. obtained its first Russian marketing approval for Elpida™ in June 2017 for treatment of HIV-1 in combination with other antiretroviral medicines. Viriom is launching Elpida™ in several developing markets, expecting to treat over 8000 HIV patients in 2017-2018. Elpida™ and elsulfavirine based fixed dose combinations and elsulfavirine once weekly dosing regimen are undergoing market registration and development in several countries including Thailand, countries of the Eurasian Economic Union and the USA.
About Viriom: Viriom focuses on the treatment, prophylaxis, and eradication of infectious diseases globally. Viriom is developing and commercializing the most innovative and affordable solutions to radically expand global access to antiviral treatments. Viriom's broad, proprietary, and partnered pipeline covers therapeutic, prophylactic, and curative medicines for HIV and viral hepatitis. Learn more at www.viriom.com.
Media Contact:
Ronald Demuth, CFO, Viriom
+1(858)-724-0581
rdemuth@viriom.com
Safe Harbor Statement
This document may contain forward-looking statements. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to publicly communicate future expectations. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, the uncertainties associated with product development, the market for our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change. The information in this document is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. The future expectations, estimations, anticipated events, results, milestones, events, operating and financial information contained in the company's financial projections and all other areas of this document are for illustrative purposes only and are based upon hypothetical assumptions and events over which the company has only partial or no control. All information about future events (projections) were developed by the company's management and are based upon a variety of assumptions with or without benefit of an operating history. The projections are included solely to provide information concerning the company's estimates of future operating results based on these assumptions and, although the company believes that these assumptions are reasonable, they may be incomplete or incorrect, and unanticipated events and circumstances may occur. Actual results will vary from the projections, and these variations may be material and adverse. The projections should be read in conjunction with the assumptions upon which the projections are based. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from our projections or the assumptions underlying them.